SMS Pharmaceuticals Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for SMS Pharmaceuticals.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 17.4% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Risks Still Elevated At These Prices As SMS Pharmaceuticals Limited (NSE:SMSPHARMA) Shares Dive 25%
Nov 14
SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Sep 07SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be Increased To ₹0.40
Aug 22Earnings Not Telling The Story For SMS Pharmaceuticals Limited (NSE:SMSPHARMA) After Shares Rise 27%
Aug 20SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹0.40
Aug 08What SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 27% Share Price Gain Is Not Telling You
Jul 04Here's Why SMS Pharmaceuticals (NSE:SMSPHARMA) Can Manage Its Debt Responsibly
Jun 21SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) 25% Share Price Surge Not Quite Adding Up
Feb 29SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation Is Looking A Bit Stretched At The Moment
Sep 24SMS Pharmaceuticals' (NSE:SMSPHARMA) Dividend Will Be ₹0.30
Sep 11SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 28SMS Pharmaceuticals (NSE:SMSPHARMA) Has A Somewhat Strained Balance Sheet
Jun 07Shareholders May Not Be So Generous With SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation And Here's Why
Sep 23SMS Pharmaceuticals (NSE:SMSPHARMA) Is Due To Pay A Dividend Of ₹0.30
Sep 15SMS Pharmaceuticals (NSE:SMSPHARMA) Will Pay A Dividend Of ₹0.30
Sep 01SMS Pharmaceuticals (NSE:SMSPHARMA) Has Announced A Dividend Of ₹0.30
Aug 18We Think SMS Pharmaceuticals (NSE:SMSPHARMA) Can Stay On Top Of Its Debt
Mar 22SMS Pharmaceuticals' (NSE:SMSPHARMA) Earnings Are Of Questionable Quality
Jun 03Should You Be Adding SMS Pharmaceuticals (NSE:SMSPHARMA) To Your Watchlist Today?
Mar 08What Type Of Shareholders Make Up SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Share Registry?
Feb 22The SMS Pharmaceuticals (NSE:SMSPHARMA) Share Price Is Up 185% And Shareholders Are Boasting About It
Feb 08SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 18
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SMS Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2024 | 7,685 | 593 | -382 | 653 | N/A |
| 6/30/2024 | 7,384 | 570 | N/A | N/A | N/A |
| 3/31/2024 | 7,093 | 498 | -20 | 501 | N/A |
| 12/31/2023 | 6,129 | 361 | N/A | N/A | N/A |
| 9/30/2023 | 6,002 | 288 | 343 | 751 | N/A |
| 6/30/2023 | 5,930 | 150 | N/A | N/A | N/A |
| 3/31/2023 | 5,221 | -71 | -75 | 225 | N/A |
| 12/31/2022 | 4,335 | -42 | N/A | N/A | N/A |
| 9/30/2022 | 4,060 | 9 | -221 | -49 | N/A |
| 6/30/2022 | 4,211 | 259 | N/A | N/A | N/A |
| 3/31/2022 | 5,199 | 622 | 178 | 451 | N/A |
| 12/31/2021 | 6,348 | 789 | N/A | N/A | N/A |
| 9/30/2021 | 6,612 | 911 | -325 | 815 | N/A |
| 6/30/2021 | 6,172 | 791 | N/A | N/A | N/A |
| 3/31/2021 | 5,632 | 625 | -613 | 905 | N/A |
| 12/31/2020 | 4,911 | 458 | N/A | N/A | N/A |
| 9/30/2020 | 4,226 | 319 | -239 | 482 | N/A |
| 6/30/2020 | 4,130 | 308 | N/A | N/A | N/A |
| 3/31/2020 | 4,143 | 316 | -30 | 397 | N/A |
| 12/31/2019 | 4,206 | 386 | N/A | N/A | N/A |
| 9/30/2019 | 4,412 | 405 | -149 | 330 | N/A |
| 6/30/2019 | 4,606 | 406 | N/A | N/A | N/A |
| 3/31/2019 | 4,667 | 400 | 149 | 498 | N/A |
| 3/31/2018 | 4,639 | 317 | N/A | 318 | N/A |
| 3/31/2017 | 4,388 | 285 | N/A | 735 | N/A |
| 3/31/2016 | 6,032 | 409 | N/A | 612 | N/A |
| 12/31/2015 | 5,902 | 391 | N/A | N/A | N/A |
| 9/30/2015 | 5,828 | 396 | N/A | N/A | N/A |
| 6/30/2015 | 5,651 | 343 | N/A | N/A | N/A |
| 3/31/2015 | 5,793 | 352 | N/A | 789 | N/A |
| 12/31/2014 | 5,730 | 358 | N/A | N/A | N/A |
| 9/30/2014 | 5,624 | 327 | N/A | N/A | N/A |
| 6/30/2014 | 5,567 | 326 | N/A | N/A | N/A |
| 3/31/2014 | 5,180 | 204 | N/A | 651 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if SMSPHARMA's forecast earnings growth is above the savings rate (6.7%).
Earnings vs Market: Insufficient data to determine if SMSPHARMA's earnings are forecast to grow faster than the Indian market
High Growth Earnings: Insufficient data to determine if SMSPHARMA's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if SMSPHARMA's revenue is forecast to grow faster than the Indian market.
High Growth Revenue: Insufficient data to determine if SMSPHARMA's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SMSPHARMA's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/09 13:06 |
| End of Day Share Price | 2025/01/09 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SMS Pharmaceuticals Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anil Burra | FirstCall Research |